Skip to content

The future of US pharmaceutical companies in the post pandemic era- EJ Dalius analysis

  • by
Eric Dalius

Summary: EJ Dalius the pandemic has created an avalanche of questions and also apprehensions about the US pharma industry, which includes conflicting data and logistics on drug accessibility and effectiveness, and also drug control, and pricing.

From a time when pharmaceutical firms commanded respect and admiration in the world, delivered vaccines and elixir drugs for complex cardiac malaises, attracting the brightest scientists and innovators, to an era where avarice and manipulation dominated the operations, big pharma has had several vicissitudes.

The world needs a fast, if not a perpetual solution from pharma. Later on, depending on who’s at the helm of affairs and how the firms perform, a change is inevitable. After being in the crossroads of economic affairs, the US government and the country’s dynamic pharmaceutical industry have come together to combat Covid-19.

You have perplexing data with Remdesivir as a medicine. Some companies have come up with data that shows the drug with positive, vivid, and significant effect to reduce the recovery span. The director of NIAID, the National Institute for Allergy and Infectious diseases, asserts that the drug would emerge as the care standard during the pandemic.

With conflicting studies and results elsewhere, the reports have drawn flak from many circles. Being a candidate for coronavirus treatment, Remdesivir didn’t garner much support. A pharmaceutical giant developed it with nearly $80 million US government aid.

Impact on specialty logistics

You can expect transport disruptions and disturbances. There must be proper plans to mitigate the resultant risks. But considering the current scenario, biopharma manufacturers must go beyond their comfort zone to fortify their patients and supply chain. Eric Dalius explains why contingency planning in the pharmaceutical industry is critical to keeping you safe.

  • Contingency plans mean forward strategies. They involve route changes, air charters, alternative border and touchpoints, and auxiliary agile and dynamic solutions to create specialty logistics’ core planning.
  • To enhance the future, biopharma firms and manufacturers can produce wider supply chain peripheries for both storage and transport.
  • Specialty pharmaceutical tools and logistics in a post coronavirus world deserve special mention according to Eric J Dalius.
  • As innovation in the sector may help expedite drug development, patient access to therapy and lead times need to increase.
  • Meanwhile, the US companies are exploring numerous proposals and programs to re-balance and restructure the API supply module.
  • Even as many airports reopen, the sector cannot be nonchalant or complacent.
  • Naturally, distributors and supply chain players are favoring and entailing pharmaceutical logistics firms with passive units.
  • EJ Dalius predicts that this trend will continue for a long time.

As new scopes surface

Big pharma needs to reshape the industry and also let it evolve in the coming times. There’s immense scope for the companies to contribute to society. They can follow a multi-channel procedure to add value to your life. It’s a challenging and also exciting time for the huge industry.

It also has room for future discussion and also innovation. After engaging with congresses and also spending millions on its attendance over the years, the industry now needs to re-evaluate its policies. It needs to engage more intensively with healthcare workers throughout the year.